For a breakdown of drug treatments administered to patients with HF based on sex, it has been observed that treatment based on evidence, such as beta-blockers, renin-angiotensin-aldosterone system blockers (ACE inhibitors, ARBs, ARNI), MRA, and SGLT-2 inhibitors, is more commonly used in men than in women among individuals with HF. The gene discussed is SLC5A2; the disease is hydrops fetalis.